Upcoming Events

Join STAT’s Washington correspondents Lev Facher and Nick Florko and Washington editor Erin Mershon for a live chat on Thursday Nov. 8 to unpack the results of the 2018 midterms. We’ll look at how health care issues like drug pricing played in key races, fill in the blanks on state-level politics and ballot initiatives, and explain what the new, incoming Congress will mean for policymaking around health, science, and medicine.

Register now

Biologic drugs — used to treat diseases such as rheumatoid arthritis and cancer — accounted for 70 percent of the growth in U.S. prescription drug spending from 2010 to 2015. Policymakers in Washington, including the FDA’s Scott Gottlieb, are pushing biosimilars as a way to introduce competition into the biologics market and restrain their price increases — and have recently released a slate of policies intended to reinvigorate the market.

But the experience so far raises questions about the effectiveness of this strategy: Many biosimilars approved by the FDA have not made it onto the U.S. market, even as they’re being sold in Europe, while other biosimilars have been approved by European regulators but not by the FDA. Join STAT senior writer and Pharmalot columnist Ed Silverman and STAT Washington correspondent Nick Florko as they discuss why.

Register now

A marquis event among industry and advocacy professionals as well as disease foundations and patient organizations, the Summit is focused on showcasing best practices and cutting-edge examples of how life sciences companies can more fully incorporate the patient voice into the work they do—not just approaching regulatory applications or at commercialization, but throughout the drug development cycle.

This year, MassBio is taking their Patient Advocacy Summit to the next level and making it more interactive than ever. Not only will you hear inspirational stories from patients, the program also includes breakout sessions to dive into metrics around PA, pain points depending on what department it sits in, FDA guidance on patient experience data, and more. The event will open with a keynote address, and attendees will have ample networking opportunities during breakfast, lunch and a cocktail reception.

Register now

This talk delves into a fascinating story that takes place at the intersection of science, medical practice, and human tragedy and resilience, and also covers the role journalism can play in impacting all three areas. The resulting impact is changing the lives of millions around the globe.

Register now

MORE INFO: The internationally known public health investigative journalist David Tuller, DrPH, is playing a leading role in a global effort to re-examine of how the highly disabling disease ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) was wrongly psychologized, causing great harm to the 24+ million people with ME/CFS around the world. David will discuss his experience as a journalist covering this huge yet underreported story. ME/CFS is a chronic, debilitating, serious illness that disables 1 – 2.5 million Americans; yet, for decades the medical community has been dismissing the disease.

The 9th annual World Orphan Drug Congress is the marketplace for orphan drug professionals looking at the complete value chain of orphan drug development, from clinical development and R&D, to corporate development and market access.

Now recognized as the largest and most established European orphan drug event, this year will deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape.

Regardless of whether your interest lies in research, clinical development, patient access, global pricing and reimbursement or just to engage with patient advocacy groups more intimately, we have content, networking and potential partners for you! Take just three days out of the office to meet with 500+ potential customers who need to find solutions to challenges around the commercial, regulatory and scientific issues in orphan drugs. Through strategic keynote plenaries, themed tracks and dedicated networking sessions, you have the chance to really tailor the event to the needs of your day-to-day role.

The 2018 Advisory Board members include:
• Wills Hughes-Wilson, Former Senior Vice President, Chief Patient Access Officer, Sobi
• Professor Michael Linden, Former VP Gene Therapy & Head, GMI, Pfizer
• Yann Le Cam, Chief Executive Officer, EURORDIS
• Dr Ségolène Aymé, Founder of Orphanet, Emeritus Research Director, INSERM
• Dr Bruno Sepodes, Chair of COMP, EMA
• Sheela Upadhyaya, Assoc. Director Highly Specialised Technologies, National Institute For Health and Care Excellence
• Alastair Kent, Director, Genetic Alliance UK
• Dr Carlo Incerti, SVP, Head of Global Medical Affairs, CMO, Genzyme, A Sanofi Company
• Dr Birgitte Volck, SVP, Head of R&D Rare Diseases, GSK
• Dr Mathew Pletcher, Head of Rare Disease Discovery, Roche
• Dr M Ken Kengatharan, Managing Director, Atheneos Capital
• Dr Pedro Franco, Former Scientific Administrator, EMA

Register today and benefit from the 10% partner discount by using the voucher code KQLD.

Register now

One of the most important and challenging leadership roles within healthcare is the “Chief Medical Officer.” As senior physicians tasked with providing leadership to increasingly diverse medical staffs during times of unrivaled challenge and uncertainty, the leadership style of a CMO is absolutely essential for stability and sustained success.

The role of Chief Medical Officers is changing dramatically as they face a new set of challenges such as new Medicare & Medicaid rules, understanding what the Trump Administration means for healthcare, finance & technology in addition to their main role of improving quality of care while reducing costs and developing a medical leadership team.

This event is focused on the end-user Chief Medical Officer and told by other Chief Medical Officers in terms of topics/issues/perspectives and case studies to discuss these new challenges in a manner that allows the attendees great actionable takeaways.

Register now

The 14th Annual Personalized Medicine Conference: Preparing for the New Possible will convene the world’s leading researchers, investors, industry executives, policy experts, payers, clinicians, and patient advocates to define the landscape and outlook for personalized medicine in science, business, and policy. Participants will examine the infrastructure and business strategies necessary to overcome scientific obstacles, optimize public policies, and change embedded medical norms as we seek to accelerate investment in and adoption of personalized medicine.

Register now

U.S. News & World Report brings its legacy of health care reporting, analysis, and industry insights to life in this annual leadership forum. Healthcare of Tomorrow, presented by U.S. News Best Hospitals, unites the nation’s top healthcare leaders–medical experts, hospital executives, policymakers, insurers, consumer advocates and industry analysts to exchange ideas, share best practices, and set new standards for patient care. The sixth annual event will be held in Washington, D.C., from November 14-16, 2018.

Register now